APAmit N. Patel

Amit N. Patel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amit N. Patel has a total of 272 co-authors. Here are the top co-authors by number of shared publications:

  • Eulsoon Park

    Center for Cardiac Cell Therapy-Heart Lung Esophageal Surgical Institute, University of Pittsburgh/UPMC/McGowan Institute of Regenerative Medicine, Pittsburgh, PA, USA

    2 shared publications
  • Federico Benetti

    Benetti Foundation, Rosario, Argentina

    2 shared publications
  • Michael Kuzman

    Center for Cardiac Cell Therapy-Heart Lung Esophageal Surgical Institute, University of Pittsburgh/UPMC/McGowan Institute of Regenerative Medicine, Pittsburgh, PA, USA

    2 shared publications
  • A. Marc Gillinov

    1 shared publication
  • Abeel A. Mangi

    Section of Cardiac Surgery, Yale University School of Medicine, New Haven, Connecticut

    1 shared publication
  • Aditya Krishna Kaza

    Department of Cardiac Surgery, Boston Children's Hospital, Boston, Massachusetts.; Department of Surgery, Harvard Medical School, Boston, Massachusetts.

    1 shared publication

Latest Publications

  • Contributors

    by Brian G. Abbott, David H. Adams, Lishan Aklog, Arvind K. Agnihotri, Louise A. Aquila Allen, Mark S. Allen, Nasser K. Altorki, Robert H. Anderson, Masaki Anraku, Anelechi C. Anyanwu, et al.

  • Open Access

    Multipotent Menstrual Blood Stromal Stem Cells: Isolation, Characterization, and Differentiation

    by Amit N. Patel, Eulsoon Park, Michael Kuzman, Federico Benetti, Francisco J. Silva, Julie G. Allickson

    The stromal stem cell fraction of many tissues and organs has demonstrated to exhibit stem cell properties such as the capability of self-renewal and multipotency, allowing for multilineage differentiation. In this study, we characterize a population of stromal stem cells derived from menstrual blood (MenSCs). We demonstrate that MenSCs are easily expandable to clinical relevance and express multipotent markers such as Oct-4, SSEA-4, and c-kit at the molecular and cellular level. Moreover, we demonstrate the multipotency of MenSCs by directionally differentiating MenSCs into chondrogenic, adipogenic, osteogenic, neurogenic, and cardiogenic cell lineages. These studies demonstrate the plasticity of MenSCs for potential research in regenerative medicine.


  • Open Access

    Cardiac Stem Cell Therapy from Bench to Bedside

    by Amit N. Patel, Warren Sherman


  • Open Access

    Improved Cell Survival in Infarcted Myocardium Using a Novel Combination Transmyocardial Laser and Cell Delivery System

    by Amit N. Patel, Cristiano Spadaccio, Michael Kuzman, Eulsoon Park, David W. Fischer, Steven L. Stice, Chandra Mullangi, Catalin Toma

    Stem cell therapy has been used to treat ischemic cardiac disease with promising early results. However, there has been limited success using cell therapy in infarcted tissue. The cells have an inadequate microvascular environment in order to survive once implanted into scar tissue. The goal of this study was to create a microvascular environment into infarcted myocardial tissue using transmyocardial laser revascularization (TMR) as a pretreatment before cell implantation and evaluate cell survival afterwards. Balloon occlusion catheter-based myocardial infarct of the circumflex artery was created in a porcine model. The infarct was allowed to mature for 2 weeks. Three groups consisting of TMR alone (TMR), TMR + fluorescent-labeled allogeneic mesenchymal stem cells (MSCs) (TMR + Cells), and MSCs alone (Cells) were injected into the infarcted tissue using a combination TMR and cell delivery system (Phoenix™, Cardiogenesis). The hearts were explanted at 1 week after treatment for cell and tissue evaluation. The myocardial infarcts were verified in all animals using both ultrasound and direct visual imaging. All arms of the study were successful with a mean of 2.0 ± 106 MSCs injected per site into the scar tissue. All animals survived to explant at 1 week. On histological examination, 300 high-power fields were evaluated demonstrating that the TMR + Cells group had 25 ± 5 cells and the Cells group 5 ± 2 cells compared to baseline TMR alone by fluorescence. The use of TMR as a pretreatment for MSC injection increases early cell survival in infarcted tissue without increased adverse events. Further long-term functional and differentiation analysis will be required to evaluate the efficacy for future clinical translation.


  • Stem cell therapy for the treatment of heart failure

    by Amit N Patel, Jorge A Genovese

    Congestive heart failure is a complex clinical syndrome resulting from myocardial dysfunction that impairs the cardiovascular system's function. Medical and surgical therapy both still result in a large number of patients with very few options and persistent ventricular dysfunction. The major process to reverse ventricular remodeling would be the enhancement of regeneration of cardiac myocytes, as well as the stimulation of neovascularization within the affected area of the myocardium. This can be achieved by introducing progenitor cells that are capable of differentiating into cardiac myocytes, or that promote neovascularization and restore the normal characteristics of myocardium environment. A number of issues remain as to the type of cells, delivery, timing, and mechanisms involved, however. There have been a number of clinical trials in patients with heart failure that have been based on animal data related to stem cell therapy. Most have utilized whole bone marrow cells or myoblasts. The majority of the studies demonstrate an improvement in ventricular function, reduction in scarring, and improvement in symptoms. Some trials have shown no improvement at all. This review examines the bench-to-bedside developments of stem cell therapy related to congestive heart failure.


  • Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study

    by Amit N. Patel, Luis Geffner, Roberto F. Vina, Jorge Saslavsky, Harold C. Urschel, Robert Kormos, Federico Benetti